Björn Dahlöf

25.4k total citations · 5 hit papers
172 papers, 16.7k citations indexed

About

Björn Dahlöf is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Björn Dahlöf has authored 172 papers receiving a total of 16.7k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Cardiology and Cardiovascular Medicine, 47 papers in Endocrinology, Diabetes and Metabolism and 18 papers in Surgery. Recurrent topics in Björn Dahlöf's work include Blood Pressure and Hypertension Studies (104 papers), Cardiovascular Function and Risk Factors (46 papers) and Hormonal Regulation and Hypertension (38 papers). Björn Dahlöf is often cited by papers focused on Blood Pressure and Hypertension Studies (104 papers), Cardiovascular Function and Risk Factors (46 papers) and Hormonal Regulation and Hypertension (38 papers). Björn Dahlöf collaborates with scholars based in Sweden, United States and Norway. Björn Dahlöf's co-authors include Hans Wedel, Lennart Hansson, Stevo Julius, Lars Lindholm, Sverre E. Kjeldsen, Markku S. Nieminen, Alberto Zanchetti, S. George Carruthers, K. H. Rahn and S. Westerling and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Björn Dahlöf

169 papers receiving 15.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

1998 4.0k citations Björn Dahlöf, Stevo Julius et al. The Lancet profile →
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

2005 1.9k citations Björn Dahlöf, Peter Sever et al. The Lancet profile →
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

1991 1.3k citations Björn Dahlöf, Lars Lindholm et al. The Lancet profile →
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2002 1.1k citations Lars Lindholm, Hans Ibsen et al. The Lancet profile →
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1999 1.0k citations Lars Lindholm, Björn Dahlöf et al. The Lancet profile →

Peers

Countries citing papers authored by Björn Dahlöf

Since Specialization

Citations

This map shows the geographic impact of Björn Dahlöf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Björn Dahlöf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Björn Dahlöf more than expected).

Fields of papers citing papers by Björn Dahlöf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Björn Dahlöf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Björn Dahlöf. The network helps show where Björn Dahlöf may publish in the future.

Co-authorship network of co-authors of Björn Dahlöf

This figure shows the co-authorship network connecting the top 25 collaborators of Björn Dahlöf. A scholar is included among the top collaborators of Björn Dahlöf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Björn Dahlöf. Björn Dahlöf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor 2023 ·Blood ·(unknown), Adriana Yamaguchi, (unknown), Sylviane Lambert, (unknown), (unknown), Catherine Luke, (unknown), T. Andrea, Andrew D. White, Niklas Bergh, Björn Dahlöf, Michael Holinstat	9
2	Racial Differences in Incident Atrial Fibrillation Among Hypertensive Patients During Antihypertensive Therapy 2014 ·American Journal of Hypertension ·Peter M. Okin, Casper N. Bang, Kristian Wachtell, Darcy A. Hille, Sverre E. Kjeldsen, Stevo Julius, Björn Dahlöf, Richard B. Devereux	5
3	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial 2012 ·The Lancet ·Michael A. Weber, Kenneth Jamerson, George L. Bakris, (unknown), Dion Zappe, Ying Zhang, Björn Dahlöf, Eric J. Velazquez, Bertram Pitt	74
4	Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy 2012 ·American Journal of Hypertension ·Eva Gerdts, Peter M. Okin, Kurt Boman, Kristian Wachtell, Markku S. Nieminen, Björn Dahlöf, Richard B. Devereux	19
5	Serial Assessment of the Electrocardiographic Strain Pattern for Prediction of New-Onset Heart Failure During Antihypertensive Treatment: The LIFE Study 2011 ·European Journal of Heart Failure ·Peter M. Okin, Lasse Oikarinen, Matti Viitasalo, Lauri Toivonen, Sverre E. Kjeldsen, Markku S. Nieminen, Jonathan M. Edelman, Björn Dahlöf, Richard B. Devereux, (unknown)	13
6	RACIAL DIFFERENCES IN SUDDEN CARDIAC DEATH AMONG HYPERTENSIVE PATIENTS DURING ANTIHYPERTENSIVE THERAPY: THE LIFE STUDY 2011 ·Journal of the American College of Cardiology ·Peter M. Okin, Sverre E. Kjeldsen, Stevo Julius, Björn Dahlöf, Richard B. Devereux	2
7	Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes 2010 ·Journal of the American College of Cardiology ·Michael A. Weber, George L. Bakris, Kenneth Jamerson, (unknown), Sverre E. Kjeldsen, Richard B. Devereux, Eric J. Velazquez, Björn Dahlöf, Roxzana Y. Kelly, Tsushung A. Hua, Allen Hester, Bertram Pitt	139
8	Abstract 1349: The Economic Consequences of Non-Adherence to Lipid-Lowering Therapy: Results From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) 2009 ·Circulation ·Peter Lindgren, Jennifer Eriksson, Martin Buxton, Thomas Kahan, Neil R Poulter, Björn Dahlöf, Peter S. Sever, Hans Wedel, Bengt Jönsson	1
9	Coronary heart disease benefits from blood pressure and lipid-lowering 2009 ·International Journal of Cardiology ·Peter Sever, Neil R Poulter, (unknown), Choon Lan Chang, Björn Dahlöf, Hans Wedel	6
10	Abstract 4421: Concomitant Hydrochlorothiazide Therapy in Hypertensive Patients is Associated with Reduced Cardiovascular Morbidity and Mortality Independent of Blood Pressure and Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study 2008 ·Circulation ·Peter M. Okin, Richard B. Devereux, Darcy A. Hille, Sverre E. Kjeldsen, Lars Lindholm, Jonathan M. Edelman, Björn Dahlöf	2
11	Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension 2007 ·Hypertension ·Neil Chapman, Joanna Dobson, (unknown), Björn Dahlöf, Peter Sever, Hans Wedel, Neil R Poulter	437
12	Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen 2007 ·Heart ·Peter Lindgren, Martin Buxton, Thomas Kahan, Neil R Poulter, Björn Dahlöf, Peter Sever, Hans Wedel, Bengt Jönsson, (unknown)	9
13	Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and left ventricular hypertrophy on ECG. : The LIFE study 2006 ·European Heart Journal ·(unknown), Kristian Wachtell, Björn Dahlöf, Lars Lindholm	1
14	Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA) 2005 ·The American Journal of Cardiology ·Peter S. Sever, Neil R Poulter, Björn Dahlöf, Hans Wedel	47
15	Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study 2005 ·Diabetic Medicine ·Per Hildebrandt, Kristian Wachtell, Björn Dahlöf, (unknown), Eva Gerdts, Thomas D. Giles, Lasse Oikarinen, Christian Tuxen, Michael Hecht Olsen, Richard B. Devereux	11
16	888-1 N-terminal pro brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: A LIFE study 2004 ·Journal of the American College of Cardiology ·Michael Hecht Olsen, Kristian Wachtell, Christian Hall, Hans Ibsen, Jens Rokkedal, Sverre E. Kjeldsen, Richard B. Devereux, Björn Dahlöf, Per Hildebrandt	6
17	882-1 Anglo-scandinavian cardiac outcomes trial — lipid-lowering arm (ASCOT-LLA): Results in the subgroup of patients with diabetes 2004 ·Journal of the American College of Cardiology ·Peter Sever, Björn Dahlöf, Neil R Poulter, Hans Wedel	4
18	Does aortic valve sclerosis predict cardiovascular events independently of albuminuria in hypertension? A LIFE study 2003 ·Journal of the American College of Cardiology ·Michael Hecht Olsen, Kristian Wachtell, Jonathan N. Bella, Vittorio Palmieri, Eva Gerdts, Markku S. Nieminen, Gunnar Smith, Björn Dahlöf, Hans Ibsen, Richard B. Devereux	2
19	Is urinary albumin excretion an independent predictor of cardiovascular mortality in patients with electrocardiographic left ventricular hypertrophy? The LIFE study 2002 ·Journal of the American College of Cardiology ·Kristian Wachtell, Michael Hecht Olsen, Björn Dahlöf, Richard B. Devereux, Stevo Julius, Sverre E. Kjeldsen, Markku S. Nieminen, Peter M. Okin, Knut Borch‐Johnsen, Hans Ibsen	1
20	A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study 2002 ·Journal of Human Hypertension ·Michael Hecht Olsen, Kristian Wachtell, K. Borch‐Johnsen, Peter M. Okin, Sverre E. Kjeldsen, Björn Dahlöf, Richard B. Devereux, Hans Ibsen	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact